Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective multicenter single-arm open-label study of darbepoetin alfa in anemic adults with myelodysplastic syndrome
2005-002414-38Phase 2Active
- Sponsor
- Fundación Española de Hematología y Hemoterapia
- Start
- Nov 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darbepoetin alfa and filgrastim in myelodysplastic syndrome (MDS), sponsored by Fundación Española de Hematología y Hemoterapia. Primary endpoint: Erythroid response rate. Started Nov 2005; status: active.
02
Drugs
darbepoetin alfafilgrastim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-002414-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002414-38.